These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17046544

  • 21. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels.
    Rivellese AA, De Natale C, Di Marino L, Patti L, Iovine C, Coppola S, Del Prato S, Riccardi G, Annuzzi G.
    J Clin Endocrinol Metab; 2004 May; 89(5):2153-9. PubMed ID: 15126535
    [Abstract] [Full Text] [Related]

  • 22. The benefits of oestrogens on postprandial lipid metabolism are lost in post-menopausal women with Type 2 diabetes.
    Masding MG, Stears AJ, Burdge GC, Wootton SA, Sandeman DD.
    Diabet Med; 2006 Jul; 23(7):768-74. PubMed ID: 16842482
    [Abstract] [Full Text] [Related]

  • 23. Increases in muscle blood flow after a mixed meal are impaired at all stages of type 2 diabetes.
    Lambadiari V, Mitrou P, Maratou E, Raptis A, Raptis SA, Dimitriadis G.
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):825-30. PubMed ID: 21950653
    [Abstract] [Full Text] [Related]

  • 24. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L, Zhao SP, Zhou HN, Li QZ, Li JX.
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [Abstract] [Full Text] [Related]

  • 25. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A.
    Przegl Lek; 2006 Jul; 63(12):1281-5. PubMed ID: 17642140
    [Abstract] [Full Text] [Related]

  • 26. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 27. Fasting triacylglycerol status, but not polyunsaturated/saturated fatty acid ratio, influences the postprandial response to a series of oral fat tolerance tests.
    Dekker MJ, Wright AJ, Mazurak VC, Marangoni AG, Rush JW, Graham TE, Robinson LE.
    J Nutr Biochem; 2009 Sep; 20(9):694-704. PubMed ID: 18829281
    [Abstract] [Full Text] [Related]

  • 28. Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion.
    Wägner AM, Ordóñez-Llanos J, Arcelus R, Bonet R, Jorba O, Sánchez-Quesada JL, Alonso E, Julve J, Pérez A.
    Metabolism; 2003 Aug; 52(8):1038-42. PubMed ID: 12898470
    [Abstract] [Full Text] [Related]

  • 29. Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients.
    Liu L, Zhao SP, Wen T, Zhou HN, Hu M, Li JX.
    Coron Artery Dis; 2008 May; 19(3):145-51. PubMed ID: 18418230
    [Abstract] [Full Text] [Related]

  • 30. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Cağlayan O, Saygili F, Yilmaz C.
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
    [Abstract] [Full Text] [Related]

  • 31. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
    Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C, Selimoglu H, Erturk E, Tuncel E, Imamoglu S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
    [Abstract] [Full Text] [Related]

  • 32. Prebeta1-HDL is elevated in the fasting state, but markedly reduced postprandially in poorly controlled type 2 diabetic patients.
    Hirayama S, Ito T, Miyazaki O, Kamimura T, Hanyu O, Seino U, Ito S, Aizawa Y, Miida T.
    Clin Chim Acta; 2009 Mar; 401(1-2):57-62. PubMed ID: 19056371
    [Abstract] [Full Text] [Related]

  • 33. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
    Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O.
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
    [Abstract] [Full Text] [Related]

  • 34. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW.
    Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
    [Abstract] [Full Text] [Related]

  • 35. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 36. Postprandial lipaemia in patients with impaired fasting glucose, impaired glucose tolerance and diabetes mellitus.
    Madhu SV, Kant S, Srivastava S, Kant R, Sharma SB, Bhadoria DP.
    Diabetes Res Clin Pract; 2008 Jun; 80(3):380-5. PubMed ID: 18321605
    [Abstract] [Full Text] [Related]

  • 37. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
    Ogawa S, Takeuchi K, Ito S.
    Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
    [Abstract] [Full Text] [Related]

  • 38. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
    Harmanci A, Kandemir N, Dagdelen S, Gonc N, Buyukasik Y, Alikasifoglu A, Kirazli S, Ozon A, Gurlek A.
    J Diabetes Complications; 2006 Sep; 20(1):40-4. PubMed ID: 16389166
    [Abstract] [Full Text] [Related]

  • 39. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
    Umpaichitra V, Hussain MM, Castells S.
    Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
    [Abstract] [Full Text] [Related]

  • 40. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.